Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295756 | 0.92 | TGFBR1 (0.64) | ROCK2TGFBR1ROCK1ABCG2MEN1 | |
| SCHEMBL22201442 | 0.85 | HPGD (0.64) | TGFBR1ABCG2MEN1KMT2AMAPT | |
| SCHEMBL2295528 | 0.82 | KDM1A (0.64) | ROCK2ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL2296338 | 0.81 | ABCG2 (0.70) | TGFBR1ABCG2MEN1KMT2AMAPT | |
| SCHEMBL2236290 | 0.81 | ABCG2 (0.52) | ABCG2MEN1KMT2AMAPTGAA | |
| SCHEMBL2294276 | 0.81 | ABCG2 (0.78) | ABCG2MEN1KMT2AMAPTGAA | |
| SCHEMBL13154697 | 0.80 | TGFBR1 (0.71) | ROCK2TGFBR1ROCK1ABCG2MEN1 | |
| SCHEMBL29395013 | 0.80 | TGFBR1 (0.71) | ROCK2TGFBR1ROCK1ABCG2MEN1 | |
| SCHEMBL3589215 | 0.80 | TGFBR1 (0.65) | ROCK2TGFBR1ROCK1ABCG2MEN1 | |
| SCHEMBL2299801 | 0.78 | ABCG2 (0.74) | TGFBR1ABCG2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528606-B1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | LEVITZKI ALEXANDER (IL) | 2014-09-24 | — | — | EP | disclosed |
| US-8759363-B2 | Quinazoline-based T cell proliferation inhibitors | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) | 2013-05-02 | — | — | US | disclosed |
| EP-2528606-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092695-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | IL2, CD4, NFATC1 | ROCK2 598/4885TGFBR1 4629/4885ROCK1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.